2. Signaling Pathways
  3. Membrane Transporter/Ion Channel
  4. Aquaporin

Aquaporin

AQP

Aquaporins (AQPs) are integral membrane proteins that facilitate the transport of water across biological membranes along an osmotic gradient. There have been 13 AQP isoforms (AQP0-AQP12) identified in humans and rodents to date. AQP0-2, 4-6 and 8 are generally considered to be exclusively water channels, whereas AQP3, 7, 9 and 10 are referred to as aquaglyceroporins, as they are also permeated by glycerol. AQPs usually adopt a tetramer conformation within the cell membrane, with each monomer consisting of a single aqueous pore that is permeable to water. The movement of water and solutes through AQP channels is a passive process that is dependent on the concentration of the transported molecule.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-126073
    DFP00173
    		99.46%
    DFP00173 is a potent and selective aquaporin-3 (AQP3) inhibitor. DFP00173 inhibits mouse and human AQP3 with an IC50 of ～0.1-0.4 μM. DFP00173 is selective for AQP3 over the homologous AQP isoforms AQP7 and AQP9.
    DFP00173
  • HY-161834
    RG100204
    		Inhibitor 99.50%
    RG100204 is a selective, orally available inhibitor of the aquaporin AQP9. RG100204 directly inhibits AQP9 channel function, preventing the transmembrane transport of water, glycerol, and H2O2. RG100204 reduces the activation of the NLRP3 inflammasome and p38 MAPK signaling pathways, thereby alleviating inflammation and pyroptosis. RG100204 reduces multi-organ dysfunction in a mouse sepsis model and shows glucose-regulating effects in diabetic db/db mice.
    RG100204
  • HY-115460
    AER-271
    AER-271, a phosphonate proagent derivative of AER-270, is an aquaporin-4 (AQP4) inhibitor for the research of acute ischemic stroke.
    AER-271
  • HY-W176557
    TGN-073
    		99.53%
    TGN-073 is a aquaporin 4 (AQP4) modulator, as well as an orally available, blood-brain barrier-permeable agent. TGN-073 increases the uptake and distribution of brain MRI tracers in the brain parenchyma and reduces the levels of insoluble amyloid-β 40 and β 42. TGN-073 can be used in research related to Alzheimer's disease, dementia, traumatic brain injury and pain.
    TGN-073
  • HY-N6016
    Bacopaside II
    		Inhibitor 98.86%
    Bacopaside II, an extract from the medicinal herb Bacopa monnieri. Bacopaside II is the inhibitor for AQP1 that exhibits anti-angiogenesis activity. Bacopaside II exhibits cytotoxicity and induces apoptosis in cancer cells.
    Bacopaside II
  • HY-W017091
    3-Phenoxy-1,2-propanediol
    		Inhibitor
    3-Phenoxy-1,2-propanediol (compound 15) is a weak aquaporin 4 (AQP4) inhibitor. 3-Phenoxy-1,2-propanediol is an important intermediate for pharmaceuticals.
    3-Phenoxy-1,2-propanediol
  • HY-148823
    RF03176
    		Inhibitor
    RF03176 is an aquaporin-9 (AQP-9) inhibitor, also exhibiting moderate inhibition effects on mAQP3 and mAQP7. RF03176 shows no activity against mAQP8.
    RF03176
  • HY-P991869
    Aquaporumab
    		Inhibitor
    Aquaporumab (AQmabAM) is an engineered human monoclonal IgG antibody. Aquaporumab is a selective inhibitor of aquaporin 4 (AQP4), binding tightly to AQP4 and competitively displacing AQP4-IgG from serum [1][2]. Aquaporumab significantly reduces neuromyelitis optica lesions in spinal cord slice cultures and in mice receiving intracerebral injection of AQP4-IgG and complement [1][2]. Aquaporumab can be used for research on neuromyelitis optica spectrum disorders [1][2]."}
    Aquaporumab
  • HY-126074
    Z433927330
    		98.20%
    Z433927330 is a potent and selective inhibitor of Aquaporin-7 (AQP7), less potently inhibits AQP3 and AQPs9, with IC50s of ~0.2 µM, ~0.7 µM and ~1.1 µM for mAQP7, mAQP3 and mAQP9, respectively.
    Z433927330
  • HY-110200
    TC AQP1 1
    		Inhibitor 98.03%
    TC AQP1 1 (m-Phenylenediacrylic acid) is a potent AQP1 inhibitor. TC AQP1 1 inhibits AQP1-mediated water flux in oocytes, with an IC50 of 8 μM.
    TC AQP1 1
  • HY-P10936A
    AQP4 (201-220) TFA
    		99.91%
    AQP4 (201-220) TFA is an encephalitogenic epitope of AQP-4. AQP4 (201-220) TFA can induce experimental autoimmune encephalomyelitis (EAE) (characterized by midline lesions in the brain, retinal pathology, and lesions at the grey matter/white matter border zone in the spinal cord). AQP-4 is a target antigen in neuromyelitis optica.
    AQP4 (201-220) TFA
  • HY-N2057
    Steviol
    		Inhibitor 99.85%
    Steviol is the main metabolite of steviol glycosides and an inhibitor of AQP2/CFTR. Steviol slows down the growth of renal cysts by inhibiting the activity of CFTR, reducing the expression of AQP2, and promoting the degradation of AQP2 and CFTR. Steviol can be used in the research of polycystic kidney disease.
    Steviol
  • HY-N2013
    Aristolactam I
    		Inhibitor 99.44%
    Aristolactam I is an AQP1 inhibitor and Aristolochic acid I metabolite. Aristolactam I can be isolated from Aristolochia plants. Aristolactam I downregulates Twist1 expression, increases E-cadherin expression, and activates the TGF-β/Smad signaling pathway. Aristolactam I has anticancer activity against breast cancer. Aristolactam I is nephrotoxic. Aristolactam I is mainly used in the study of breast cancer and kidney diseases such as renal interstitial fibrosis.
    Aristolactam I
  • HY-N0237
    Atractyloside A
    		Modulator 98.11%
    Atractyloside A is an orally active inhibitor of the TLR4/MyD88/NF-κB signaling pathway and also an opener of the mitochondrial permeability transition pore (MPTP). Atractyloside A interferes with the activation of the TLR4/MyD88/NF-κB pathway, thereby inhibiting intestinal inflammatory responses. Atractyloside A reverses mucin synthesis impairment, improves intestinal barrier integrity, and restores homeostasis by altering the composition of the gut microbiota. Atractyloside A can be used in studies related to spleen deficiency diarrhea and myocardial injury.
    Atractyloside A
  • HY-174166
    AqF026
    		Activator 99.05%
    AqF026 is an aquaporin 1 (AQP1) agonist. AqF026 enhances the channel activity of human AQP1 in the Xenopus laevis oocyte system. AqF026 enhances the osmotic transport of water across the peritoneum in a mouse model of peritoneal dialysis. AqF026 can be used in studies related to ultrafiltration failure in peritoneal dialysis.
    AqF026
  • HY-N4246
    Bacopaside I
    		Inhibitor 99.20%
    Bacopaside I is an orally active aquaporin AQP1 inhibitor and PKC modulator with neuroprotective and anticancer activities. Bacopaside I specifically blocks the water channel and cGMP-gated ion channel activities of AQP1 without affecting AQP4, thereby inhibiting the migration of colon cancer cells expressing AQP1. Bacopaside I activates the Akt pathway by interacting with PI3K, specifically inhibits MAO-A, effectively alleviates neuron necrosis and apoptosis induced by oxygen-glucose deprivation, reduces oxidative stress, and regulates the surface expression of neuroreceptors. When combined with Bacopaside II (HY-N6016), Bacopaside I significantly reduces the viability, proliferation and invasion ability of breast cancer cells, and binds to the pregnane X receptor (PXR). Bacopaside I is applicable to the research of colon cancer, breast cancer, vascular dementia, cerebral ischemia and other related diseases.
    Bacopaside I
  • HY-157226
    ORI-TRN-002
    		Inhibitor
    ORI-TRN-002 is an AQP4 inhibitor with an IC50 value of 3μM. ORI-TRN-002 can be used in the research area of cerebral edema.
    ORI-TRN-002
  • HY-P10937A
    AQP4 (205-215) TFA
    AQP4 (205-215) TFA is a fragment of Aquaporin-4 (AQP4). AQP4 is a neuromyelitis optica autoantigen that is upregulated and presented in B cells after engagement of CD40. AQP4 is associated with autoimmune inflammatory diseases of the central nervous system (CNS), neuromyelitis optica (NMO).
    AQP4 (205-215) TFA
  • HY-181084
    PROTAC BCL6/GSPT1 Degrader-1
    		Inducer
    PROTAC BCL6/GSPT1 Degrader-1 is a dual-target PROTAC degrader that targets BCL6 and GSPT1. PROTAC BCL6/GSPT1 Degrader-1 inhibits cell proliferation, promotes DNA damage, and induces cell cycle arrest and apoptosis in diffuse large B-cell lymphoma. PROTAC BCL6/GSPT1 Degrader-1 can be used for research on tumors such as lymphoma.
    PROTAC BCL6/GSPT1 Degrader-1
  • HY-N4246R
    Bacopaside I (Standard)
    		Inhibitor
    Bacopaside I (Standard) is the analytical standard of Bacopaside I. This product is intended for research and analytical applications. Bacopaside I is an orally active aquaporin AQP1 inhibitor and PKC modulator with neuroprotective and anticancer activities. Bacopaside I specifically blocks the water channel and cGMP-gated ion channel activities of AQP1 without affecting AQP4, thereby inhibiting the migration of colon cancer cells expressing AQP1. Bacopaside I activates the Akt pathway by interacting with PI3K, specifically inhibits MAO-A, effectively alleviates neuron necrosis and apoptosis induced by oxygen-glucose deprivation, reduces oxidative stress, and regulates the surface expression of neuroreceptors. When combined with Bacopaside II (HY-N6016), Bacopaside I significantly reduces the viability, proliferation and invasion ability of breast cancer cells, and binds to the pregnane X receptor (PXR). Bacopaside I is applicable to the research of colon cancer, breast cancer, vascular dementia, cerebral ischemia and other related diseases.
    Bacopaside I (Standard)
Cat. No. Product Name / Synonyms Application Reactivity